$0.65
-0.01 (-0.78%)
Open$0.65
Previous Close$0.66
Day High$0.68
Day Low$0.63
52W High$5.14
52W Low$0.43
Volume—
Avg Volume1.21M
Market Cap25.78M
P/E Ratio—
EPS$-1.46
SectorBiotechnology
Analyst Ratings
Sell
10 analysts
Price Target
+7,503.8% upside
Current
$0.65
$0.65
Target
$49.47
$49.47
$36.23
$49.47 avg
$53.77
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 622.0K | 819.2K | 9.03M |
| Net Income | -65,979,513 | -78,205,665 | 1.99M |
| Profit Margin | -10,579.8% | -10,050.9% | 22.0% |
| EBITDA | -71,625,391 | -89,614,278 | 3.04M |
| Free Cash Flow | — | — | 1.40M |
| Rev Growth | -24.1% | -24.1% | +1.4% |
| Debt/Equity | — | — | 0.61 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |